Benign prostatic hyperplasia (BPH) is a common condition as men age and the most common benign tumour in men. Approximately half of all men between the age of 51 and 60 years have BPH and upto 90% of men over the age of 80 years have it. Prostate enlargement can be responsible for a variety of urinary symptoms including hesitancy with poor urinary flow, frequency, nocturia and incontinence. Where surgery was once a likely outcome for this condition many medical therapies have evolved to provide suitable alternatives including Alpha 1 adrenoceptor blockers resulting in smooth muscle relaxation in the prostate and bladder neck, 5-alpha reductase inhibitors which reduce prostate volume and growth by inhibiting the conversion of testosterone to dihydrotestosterone (DITT) and phosphodiesterase 5 inhibitors which may improve quality of life and voiding symptoms.